RxDoctor Payments Data

Sarah Escott, MD

Ophthalmology · Morganton, NCNPI 1265594980

Payments from drug & device makers

$1,092in general payments, 2019–2025

Across 29 payments — averaging $37.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Notal Vision, Inc.$720
  • NEW World Medical,inc.$114
  • AbbVie$66
  • Carl Zeiss Meditec, Inc.$65
  • Biotissue Holdings Inc.$46
  • Bausch & Lomb Americas Inc.$24
  • plus $57 from 3 others

What the payments were for

  • Food & beverage$372100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,092 in reported general payments places this provider in the 40th percentile of 588 ophthalmology providers in North Carolina.

See all ophthalmology providers in North Carolina

Medicare billing

Part B allowed, 2024
$175,121
Medicare patients
877
Services billed
1,718

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine33$30,395
Latanoprost729$17,285
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat381$12,996
Travoprost39$7,765
Cyclosporine12$6,388
Brimonidine Tartrate336$6,219
CombiganBrimonidine Tartrate/Timolol21$5,615
Brinzolamide16$4,552
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol20$4,090
Prednisolone Acetate79$3,900
ValacyclovirValacyclovir Hcl39$3,413
Dorzolamide Hcl61$2,436
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha181$2,110
Ketorolac Tromethamine60$1,640
Timolol Maleate80$1,446

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Combigan$66$36,01054 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 588 ophthalmology providers in North Carolina.

Other ophthalmology in Morganton

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →